【摘要】：目的:以冠脈臨界病變患者為研究對象,觀察三生調(diào)脂舒聯(lián)合西藥治療冠脈臨界病變的臨床療效及安全性。方法:選取符合納入標準的病患78例,隨機平均分為兩組(對照組、治療組)。對照組僅用常規(guī)西藥治療,治療組在常規(guī)西藥治療基礎上加用三生調(diào)脂舒治療,連續(xù)治療12周后判斷療效。結(jié)果:1、治療過程中,三生調(diào)脂舒聯(lián)合西藥組及西藥組治療后均未發(fā)生一級、二級終點事件;對比治療前后肝功能(AST、ALT)水平、腎功能(BUN、Cr)的水平,兩組藥物均未造成指標異常(p0.05),提示三生調(diào)脂舒具有一定的安全性。2、治療后兩組冠脈狹窄程度較治療前無明顯變化,提示兩組用藥可能對延緩冠脈狹窄的發(fā)展有一定作用;兩組用藥后心絞痛癥狀積分均優(yōu)于治療前,有統(tǒng)計學意義;但兩組組間比較無顯著性差異(p0.05)。3、三生調(diào)脂舒聯(lián)合西藥與單純西藥治療均能降低冠脈臨界病變患者中醫(yī)證候總積分及頸動脈斑塊積分,但三生調(diào)脂舒聯(lián)合西藥組更具有優(yōu)勢(p0.05);中醫(yī)證候單項有效情況分析,三生調(diào)脂舒聯(lián)合西藥組在改善心悸、氣短、痞滿、肢體困重、乏力等方面效果較西藥組好;但是兩組在緩解胸悶、胸痛等方面無明顯差異(p0.05)。4、研究結(jié)果提示,兩組患者治療后血脂水平較治療前均有下降,有統(tǒng)計學意義,三生調(diào)脂舒聯(lián)合西藥組較西藥組優(yōu)勢更明顯(p0.05)。結(jié)論:三生調(diào)脂舒聯(lián)合西藥可明顯改善痰瘀互結(jié)癥狀,具有一定安全性,并且在降低頸動脈斑塊積分與血脂等方面可產(chǎn)生較好的療效,但對改善心絞痛癥狀及縮減冠脈狹窄等方面與單純使用西藥治療無顯著性差異。
[Abstract]:Objective: to observe the clinical efficacy and safety of Sansheng Tiaozhishu combined with western medicine in the treatment of coronary critical disease. Methods: 78 patients who met the inclusion criteria were randomly divided into two groups (control group, treatment group). The control group was treated with routine western medicine, while the treatment group was treated with Sansheng Tiaozhishu on the basis of routine western medicine, and the curative effect was evaluated after 12 weeks of continuous treatment. Results: 1. In the course of treatment, there were no first-grade and second-order terminal events in Sansheng Tiaozhishu combined with western medicine group and western medicine group; Compared with the levels of liver function (AST,ALT) and renal function (BUN,Cr) before and after treatment, the two groups did not cause abnormal indexes (p0. 05), suggesting that Sansheng Tiaozhi Shu was safe to some extent. The degree of coronary stenosis in the two groups did not change significantly after treatment, suggesting that the two groups may have a certain role in delaying the development of coronary artery stenosis. The symptom score of angina pectoris in the two groups was better than that before treatment, which had statistical significance. However, there was no significant difference between the two groups (p0.05). 3. Sansheng Tiaozhishu combined with western medicine and western medicine could reduce the total score of TCM syndromes and carotid plaque score in patients with critical coronary artery disease. But Sansheng Tiaozhishu combined with western medicine had more advantages (p0.05); Analysis of the single effective situation of TCM syndrome, Sansheng Tiaozhishu combined with western medicine group in improving palpitations, shortness of breath, full of ruffiness, limb distress, fatigue and other aspects of the effect is better than the western medicine group; However, there was no significant difference in relieving chest tightness and chest pain between the two groups (p0.05). The results showed that the blood lipid levels in the two groups were significantly lower than those before treatment. The advantage of Sansheng Tiaozhishu combined with western medicine group was more obvious than that of western medicine group (p 0.05). Conclusion: Sanshengtiaozhishu combined with western medicine can obviously improve phlegm and blood stasis syndrome, has certain safety, and can produce better curative effect in reducing carotid plaque score and blood lipid, etc. However, there was no significant difference between the treatment of angina pectoris and the reduction of coronary stenosis.
【學位授予單位】：云南中醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R541.4

【參考文獻】

相關期刊論文 前10條

1 侯羽宇;;用雙源CT冠狀動脈成像檢查法診斷冠心病的效果分析[J];當代醫(yī)藥論叢;2015年23期

2 陳同生;張慎和;張純燕;張立華;王紅梅;陳子_，

本文編號：2389660